Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takeshi Masuda

Showing results (231-240 of 298) with videos related to

Pageof 30
Sort By:
JAMA Network Open|November 12, 2020
Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung CancersKiyofumi Shimoji, Takeshi Masuda, Kakuhiro Yamaguchi, et al.
The European Respiratory Journal|March 10, 2018
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesotheliomaTakahiko Otsuki, Taku Nakashima, Hironobu Hamada, et al.
Cancer Science|October 26, 2020
Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancerYu Wakabayashi, Takeshi Masuda, Kazunori Fujitaka, et al.
Molecules (Basel, Switzerland)|July 21, 2019
Cyclization of Single-Chain Fv Antibodies Markedly Suppressed Their Characteristic Aggregation Mediated by Inter-Chain VH-VL InteractionsSoichiro Yamauchi, Yoshihiro Kobashigawa, Natsuki Fukuda, et al.
Bioorganic & Medicinal Chemistry Letters|September 8, 2016
Wide application of a novel topoisomerase I inhibitor-based drug conjugation technologyYusuke Ogitani, Yuki Abe, Takuma Iguchi, et al.
Leukemia|March 27, 2023
Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistanceFumihiko Nakao, Kiyoko Setoguchi, Yuichiro Semba, et al.
Anticancer Research|May 6, 2021
Prognostic Significance of <i>EGFR</i> Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care AloneTakeshi Masuda, Y U Wakabayashi, Taku Nakashima, et al.
Urologic Oncology|March 7, 2020
The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patientsKoichiro Ogihara, Eiji Kikuchi, Keisuke Shigeta, et al.
In Vivo (Athens, Greece)|August 29, 2018
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II StudyKakuhiro Yamaguchi, Takeshi Masuda, Kazunori Fujitaka, et al.
Molecular and Clinical Oncology|October 23, 2018
Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility studyTakeshi Masuda, Masako Watanabe, Kazunori Fujitaka, et al.
Pageof 30

Showing results (231-240 of 298) with videos related to

Sort By:
Pageof 30
JAMA Network Open|November 12, 2020
Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung CancersKiyofumi Shimoji, Takeshi Masuda, Kakuhiro Yamaguchi, et al.
The European Respiratory Journal|March 10, 2018
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesotheliomaTakahiko Otsuki, Taku Nakashima, Hironobu Hamada, et al.
Cancer Science|October 26, 2020
Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancerYu Wakabayashi, Takeshi Masuda, Kazunori Fujitaka, et al.
Molecules (Basel, Switzerland)|July 21, 2019
Cyclization of Single-Chain Fv Antibodies Markedly Suppressed Their Characteristic Aggregation Mediated by Inter-Chain VH-VL InteractionsSoichiro Yamauchi, Yoshihiro Kobashigawa, Natsuki Fukuda, et al.
Bioorganic & Medicinal Chemistry Letters|September 8, 2016
Wide application of a novel topoisomerase I inhibitor-based drug conjugation technologyYusuke Ogitani, Yuki Abe, Takuma Iguchi, et al.
Leukemia|March 27, 2023
Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistanceFumihiko Nakao, Kiyoko Setoguchi, Yuichiro Semba, et al.
Anticancer Research|May 6, 2021
Prognostic Significance of <i>EGFR</i> Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care AloneTakeshi Masuda, Y U Wakabayashi, Taku Nakashima, et al.
Urologic Oncology|March 7, 2020
The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patientsKoichiro Ogihara, Eiji Kikuchi, Keisuke Shigeta, et al.
In Vivo (Athens, Greece)|August 29, 2018
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II StudyKakuhiro Yamaguchi, Takeshi Masuda, Kazunori Fujitaka, et al.
Molecular and Clinical Oncology|October 23, 2018
Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility studyTakeshi Masuda, Masako Watanabe, Kazunori Fujitaka, et al.
Pageof 30